TCOV
AXSM icon

Trust Company of Vermont’s Axsome Therapeutics AXSM Stock Holding History

Trust Company of Vermont’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$73.1K Hold
400
– – ﹤0.01% 505
2025
Q3 		$48.6K Hold
400
– – ﹤0.01% 562
2025
Q2 		$41.8K Hold
400
– – ﹤0.01% 572
2025
Q1 		$46.7K Sell
400
-100
-20% -$11.4K ﹤0.01% 527
2024
Q4 		$42.3K Hold
500
– – ﹤0.01% 551
2024
Q3 		$44.9K Hold
500
– – ﹤0.01% 533
2024
Q2 		$40.3K Hold
500
– – ﹤0.01% 524
2024
Q1 		$39.9K Buy
+500
New +$42K ﹤0.01% 518

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Trust Company of Vermont's AXSM Position: Q4 2025 in Review

Trust Company of Vermont held its Axsome Therapeutics (AXSM) position steady in Q4 2025 at 400 shares worth $73.1K. The position accounts for ﹤0.01% of the portfolio, ranked #505.

Trust Company of Vermont first reported a position in AXSM in Q1 2024 and has held it in 8 quarters since. 398 funds tracked by Wall St. Rank hold AXSM as of Q4 2025.

  • Trust Company of Vermont held 400 shares of Axsome Therapeutics worth $73.1K as of Q4 2025.
  • Trust Company of Vermont left its Axsome Therapeutics share count unchanged in Q4 2025.
  • Axsome Therapeutics made up ﹤0.01% of Trust Company of Vermont's portfolio in Q4 2025, its #505 holding.
  • Trust Company of Vermont first reported a position in Axsome Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • 398 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2025.

Based on Trust Company of Vermont's 13F filing for Q4 2025, filed 16 Jan 2026.